All In Biotech

Drug Trial Radar · NCT05350072

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

275

Actual

Start

Jul 28, 2022

Primary completion

May 7, 2025

Study completion Jun 2, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-1)

Conditions

  • Sjogren Syndrome

Interventions

  • VAY736Biological

    ianalumab s.c.

  • PlaceboOther

    placebo s.c.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in EULAR Sjogren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placeboTime frame: 48 weeks

Locations

77 sites in 18 countries. Site status is shown where the registry gives one.

  • Medvin Clinical Research

    Van Nuys, California

  • West Broward Rheumatology Associates Inc

    Tamarac, Florida

  • Indiana Univ School of Dentistry

    Indianapolis, Indiana

  • Ochsner Health System

    Baton Rouge, Louisiana

  • The John Hopkins Jerome L Greene Sjogren

    Baltimore, Maryland

  • NYU Langone Hospital - Long Island

    Mineola, New York

  • Carolina Arthritis Associates

    Wilmington, North Carolina

  • STAT Research Inc

    Dayton, Ohio

  • Altoona Center for Clin Res

    Duncansville, Pennsylvania

  • Precision Comprehensive Research

    Colleyville, Texas

  • Metroplex Clinical Research

    Dallas, Texas

  • Baylor College Of Medicine

    Houston, Texas

  • Houston Rheumatology and Arthrit

    Katy, Texas

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Stockerau, Austria

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Vitória, Espírito Santo, Brazil

  • Novartis Investigative Site

    Juiz de Fora, Minas Gerais, Brazil

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, Brazil

  • Novartis Investigative Site

    Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site

    Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Baotou, Inner Mongolia, China

  • Novartis Investigative Site

    Hohhot, Inner Mongolia, China

  • Novartis Investigative Site

    Nanchang, Jiangxi, China

  • Novartis Investigative Site

    Shenyang, Liaoning, China

  • Novartis Investigative Site

    Linyi, Shandong, China

  • Novartis Investigative Site

    Taiyuan, Shanxi, China

  • Novartis Investigative Site

    Xian, Shanxi, China

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Uherské Hradiště, Czechia

  • Novartis Investigative Site

    Caen, France

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.